Product
Hyaluronidase-zzxf/Pertuzumab/Trastuzumab
Aliases
Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf, Pertuzumab/Trastuzumab/Hyaluronidase-zzxf, Phesgo
3 clinical trials
17 indications
Indication
Breast CarcinomaIndication
Malignant NeoplasmIndication
Ovarian CancerIndication
Pancreatic CarcinomaIndication
Prostate CancerIndication
Advanced SarcomaIndication
Breast CancerIndication
Breast Cancer, Stage IVIndication
Soft Tissue SarcomaIndication
Recurrent Ovarian CarcinomaIndication
Pancreatic CancerIndication
Stage III Ovarian Cancer AJCC v8Indication
Stage III Pancreatic CancerIndication
Stage IV Ovarian CancerIndication
Castration-Resistant Prostate CarcinomaIndication
Endometrial Serous AdenocarcinomaIndication
Uterine CarcinosarcomaClinical trial
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial: Adaptive Clinical Treatment (ACT)Status: Withdrawn, Estimated PCD: 2026-05-31
Clinical trial
Phase II Trial of Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (HP) Plus Enzalutamide for the Treatment of Selected Patients With Metastatic Castration-Resistant Prostate Cancer (TraPPer)Status: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf (PHESGO) in HER2 Positive, Stage I-IV Endometrial Serous Carcinoma or CarcinosarcomaStatus: Recruiting, Estimated PCD: 2027-10-31